Equillium Inc (EQ)

$1.88 -0.04 (-2.08%)
Market Cap 127.09M
Revenue (ttm) 0.00
Net Income (ttm) -22.40M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 195,023
Avg Vol 522,556
Day's Range N/A - N/A
Shares Out 63.23M
Stochastic %K 75%
Beta 1.75
Analysts Sell
Price Target $5.50

Company Profile

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 240 1200
Address:
2223 Avenida De La Playa, Suite 105, La Jolla, United States
Word0025
Word0025 Apr. 6 at 2:46 PM
$EQ SMALL RUN AT ALMOST 5% GAIN
0 · Reply
Word0025
Word0025 Apr. 6 at 1:25 PM
$EQ HAD PREMARKET EARNINGS
0 · Reply
focafoca99
focafoca99 Apr. 3 at 8:28 PM
$EQ granted inducement stock options covering 32,000 shares to a new employee.
0 · Reply
focafoca99
focafoca99 Mar. 31 at 1:50 AM
$EQ's proxy is not just routine AGM paper; it also asks shareholders to approve a possible reverse split of anywhere from 1-for-2 to 1-for-20.
0 · Reply
BladeKingShadowLordX
BladeKingShadowLordX Mar. 30 at 10:10 PM
$EQ bandit is broke gg.
0 · Reply
Publicola29
Publicola29 Mar. 30 at 5:17 PM
$EQ be interesting to see where this goes if the drug works. That's a big IF
0 · Reply
LordFawkwadReturns
LordFawkwadReturns Mar. 27 at 9:29 PM
$EQ Add zone
0 · Reply
BanditQ
BanditQ Mar. 27 at 1:13 PM
$EQ im making $1300 for every cent this stock rises
1 · Reply
StockConsultant
StockConsultant Mar. 27 at 12:24 PM
$EQ Equillium stock, nice trend with a pullback to 1.98 support area with bullish indicators at https://stockconsultant.com/?EQ
0 · Reply
Aborshd
Aborshd Mar. 26 at 2:42 AM
$EQ
0 · Reply
Latest News on EQ
Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists

Apr 8, 2026, 8:30 AM EDT - 5 hours ago

Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 2, 2026, 4:05 PM EDT - 5 days ago

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights

Mar 25, 2026, 4:05 PM EDT - 13 days ago

Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights

Equillium to Participate in the 38th Annual Roth Conference

Mar 18, 2026, 8:30 AM EDT - 21 days ago

Equillium to Participate in the 38th Annual Roth Conference

Equillium Announces $35 Million Financing with RA Capital Management

Mar 13, 2026, 8:00 AM EDT - 26 days ago

Equillium Announces $35 Million Financing with RA Capital Management

Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference

Feb 25, 2026, 8:30 AM EST - 6 weeks ago

Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference

Equillium to Participate in Upcoming Investor Conferences

Nov 20, 2025, 4:35 PM EST - 4 months ago

Equillium to Participate in Upcoming Investor Conferences

Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update

Nov 13, 2025, 4:05 PM EST - 5 months ago

Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update

Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025

Oct 22, 2025, 8:00 AM EDT - 6 months ago

Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025

Equillium Announces Leadership and Corporate Updates

Oct 6, 2025, 4:02 PM EDT - 6 months ago

Equillium Announces Leadership and Corporate Updates

NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor

Sep 23, 2025, 5:30 AM EDT - 7 months ago

NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor

Equillium to Participate in the Cantor Global Healthcare Conference 2025

Aug 29, 2025, 4:03 PM EDT - 7 months ago

Equillium to Participate in the Cantor Global Healthcare Conference 2025

Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic

Aug 11, 2025, 8:30 AM EDT - 8 months ago

Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic

Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy

Aug 4, 2025, 8:30 AM EDT - 8 months ago

Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy

Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists

May 6, 2025, 8:00 AM EDT - 1 year ago

Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists

Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

May 1, 2025, 8:00 AM EDT - 1 year ago

Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

Equillium Announces Feedback from the U.S. Food and Drug Administration

Apr 24, 2025, 9:00 AM EDT - 1 year ago

Equillium Announces Feedback from the U.S. Food and Drug Administration

Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients

Mar 27, 2025, 11:16 AM EDT - 1 year ago

Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

Feb 6, 2025, 8:00 AM EST - 1 year ago

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

Nov 13, 2024, 4:01 PM EST - 1 year ago

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

Equillium to Present at the Stifel Healthcare Conference

Nov 13, 2024, 8:00 AM EST - 1 year ago

Equillium to Present at the Stifel Healthcare Conference

Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer

Nov 12, 2024, 8:00 AM EST - 1 year ago

Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer

Equillium Maintains Rights to Itolizumab Following Ono Partnership

Oct 31, 2024, 7:00 AM EDT - 1 year ago

Equillium Maintains Rights to Itolizumab Following Ono Partnership

Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer

Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference

Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights

Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance

Jul 18, 2024, 1:57 PM EDT - 1 year ago

Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance

Equillium to be included in the Russell Microcap® Index

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Equillium to be included in the Russell Microcap® Index

Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata

Jun 4, 2024, 8:00 AM EDT - 2 years ago

Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata

Equillium to Present at the Jefferies Global Healthcare Conference

May 29, 2024, 8:00 AM EDT - 2 years ago

Equillium to Present at the Jefferies Global Healthcare Conference

Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

May 14, 2024, 8:00 AM EDT - 2 years ago

Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights

May 9, 2024, 4:01 PM EDT - 2 years ago

Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

May 7, 2024, 8:00 AM EDT - 2 years ago

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

Mar 25, 2024, 4:01 PM EDT - 2 years ago

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference

Mar 22, 2024, 8:00 AM EDT - 2 years ago

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

Dec 21, 2023, 8:00 AM EST - 2 years ago

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

Nov 13, 2023, 9:00 AM EST - 2 years ago

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Nov 8, 2023, 4:01 PM EST - 2 years ago

Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Nov 6, 2023, 8:00 AM EST - 2 years ago

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology

Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium

Equillium to Host Analyst & Investor Day

Oct 3, 2023, 8:00 AM EDT - 2 years ago

Equillium to Host Analyst & Investor Day

Equillium to Present at the JonesTrading 2023 Healthcare Summit

Oct 2, 2023, 8:00 AM EDT - 2 years ago

Equillium to Present at the JonesTrading 2023 Healthcare Summit

Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences

Sep 20, 2023, 8:00 AM EDT - 2 years ago

Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences

Word0025
Word0025 Apr. 6 at 2:46 PM
$EQ SMALL RUN AT ALMOST 5% GAIN
0 · Reply
Word0025
Word0025 Apr. 6 at 1:25 PM
$EQ HAD PREMARKET EARNINGS
0 · Reply
focafoca99
focafoca99 Apr. 3 at 8:28 PM
$EQ granted inducement stock options covering 32,000 shares to a new employee.
0 · Reply
focafoca99
focafoca99 Mar. 31 at 1:50 AM
$EQ's proxy is not just routine AGM paper; it also asks shareholders to approve a possible reverse split of anywhere from 1-for-2 to 1-for-20.
0 · Reply
BladeKingShadowLordX
BladeKingShadowLordX Mar. 30 at 10:10 PM
$EQ bandit is broke gg.
0 · Reply
Publicola29
Publicola29 Mar. 30 at 5:17 PM
$EQ be interesting to see where this goes if the drug works. That's a big IF
0 · Reply
LordFawkwadReturns
LordFawkwadReturns Mar. 27 at 9:29 PM
$EQ Add zone
0 · Reply
BanditQ
BanditQ Mar. 27 at 1:13 PM
$EQ im making $1300 for every cent this stock rises
1 · Reply
StockConsultant
StockConsultant Mar. 27 at 12:24 PM
$EQ Equillium stock, nice trend with a pullback to 1.98 support area with bullish indicators at https://stockconsultant.com/?EQ
0 · Reply
Aborshd
Aborshd Mar. 26 at 2:42 AM
$EQ
0 · Reply
BanditQ
BanditQ Mar. 25 at 11:06 PM
$EQ $SRPT
0 · Reply
AceofDiamonds
AceofDiamonds Mar. 25 at 10:45 PM
$EQ After the data is released 6 months post start of the study undoubtedly EQ will sell if the data is good ( which looks very promising due to the huge sums of money given recently ). These financial institutions think the same way it’s highly likely it will be successful. Could be a multi billion dollar exit. Expect a steady uptick in share price especially when the study starts. Easily 15 to 20.00 here post data hence the recent 12.00 price target given by a major analyst. Big money to be made here.
0 · Reply
kellyCriterion101
kellyCriterion101 Mar. 25 at 9:24 PM
$EQ earnings nuggets EQ302 unveiled: preclinical, first-in-class oral IL-15/IL-21 inhibitor targeting GI diseases incl. celiac; no IND or Ph1 timeline disclosed yet.
1 · Reply
kellyCriterion101
kellyCriterion101 Mar. 25 at 9:23 PM
$EQ earnings nuggets EQ504 update: Ph1 on track for mid-2026 start with data ~6 months later; Ph1b/2 in UC to follow. Preclinical DSS data vs cyclosporin/indirubin reiterated. New info: Scope broadened to UC + GI & lung inflammation; pouchitis mention dropped.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 25 at 12:21 AM
$EQ RSI: 57.35, MACD: 0.1225 Vol: 0.20, MA20: 1.99, MA50: 1.65 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BanditQ
BanditQ Mar. 20 at 8:27 PM
$EQ people don't realise how huge this is. No safety concerns like indigo naturalis because of this! $ABVX
0 · Reply
BanditQ
BanditQ Mar. 18 at 8:12 PM
$ABVX $CAPR $EQ haven't sold a single share 💀
3 · Reply
LordFawkwadReturns
LordFawkwadReturns Mar. 18 at 8:03 PM
$EQ Held $2.10 like a fucking G
0 · Reply
LordFawkwadReturns
LordFawkwadReturns Mar. 18 at 3:21 PM
$EQ Volume dried up
0 · Reply
BanditQ
BanditQ Mar. 18 at 8:08 AM
$ABVX $EQ
0 · Reply
ASseenONtv
ASseenONtv Mar. 17 at 12:33 AM
$EQ looks like someone maybe exiting.
1 · Reply
ASseenONtv
ASseenONtv Mar. 17 at 12:32 AM
$EQ Am I correct that the COO sold another large chunk of her stock last week?
0 · Reply